Solara Active Pharma Sciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 5, 2025, 7:01 pm

Competitors of Solara Active Pharma Sciences Ltd

All Competitor Stocks of Solara Active Pharma Sciences Ltd

Quarterly Result

Last Updated: August 1, 2025, 11:20 am

Below is a detailed analysis of the quarterly data for Solara Active Pharma Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 319.00 Cr.. The value appears strong and on an upward trend. It has increased from 273.00 Cr. (Mar 2025) to 319.00 Cr., marking an increase of 46.00 Cr..
• For Expenses, as of Jun 2025, the value is 262.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 228.00 Cr. (Mar 2025) to 262.00 Cr., marking an increase of 34.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 12.00 Cr..
• For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 17.00% (Mar 2025) to 18.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 24.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 29.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 5.00 Cr..
• For Depreciation, as of Jun 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 13.00 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
• For Net Profit, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from -2.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 13.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.91. The value appears strong and on an upward trend. It has increased from -0.58 (Mar 2025) to 2.91, marking an increase of 3.49.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:24 am

Growth

Last Updated: September 5, 2025, 1:31 pm

Balance Sheet

Last Updated: December 4, 2025, 2:00 am

Below is a detailed analysis of the balance sheet data for Solara Active Pharma Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2025) to 44.00 Cr., marking an increase of 4.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,054.00 Cr. (Mar 2025) to 1,210.00 Cr., marking an increase of 156.00 Cr..
• For Borrowings, as of Sep 2025, the value is 646.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 796.00 Cr. (Mar 2025) to 646.00 Cr., marking a decrease of 150.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 393.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 342.00 Cr. (Mar 2025) to 393.00 Cr., marking an increase of 51.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 2,293.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,232.00 Cr. (Mar 2025) to 2,293.00 Cr., marking an increase of 61.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 1,232.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,193.00 Cr. (Mar 2025) to 1,232.00 Cr., marking an increase of 39.00 Cr..
• For CWIP, as of Sep 2025, the value is 230.00 Cr.. The value appears to be declining and may need further review. It has decreased from 280.00 Cr. (Mar 2025) to 230.00 Cr., marking a decrease of 50.00 Cr..
• For Investments, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
• For Other Assets, as of Sep 2025, the value is 829.00 Cr.. The value appears strong and on an upward trend. It has increased from 757.00 Cr. (Mar 2025) to 829.00 Cr., marking an increase of 72.00 Cr..
• For Total Assets, as of Sep 2025, the value is 2,293.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,232.00 Cr. (Mar 2025) to 2,293.00 Cr., marking an increase of 61.00 Cr..

Notably, the Reserves (1,210.00 Cr.) exceed the Borrowings (646.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Solara Active Pharma Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
• For Cash EPS (Rs.), as of Mar 25, the value is 24.79. This value is within the healthy range. It has increased from -128.79 (Mar 24) to 24.79, marking an increase of 153.58.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 318.95. It has decreased from 358.03 (Mar 24) to 318.95, marking a decrease of 39.08.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 53.32. This value is within the healthy range. It has increased from -24.95 (Mar 24) to 53.32, marking an increase of 78.27.
• For PBIT / Share (Rs.), as of Mar 25, the value is 28.66. This value is within the healthy range. It has increased from -53.65 (Mar 24) to 28.66, marking an increase of 82.31.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from -135.67 (Mar 24) to 0.13, marking an increase of 135.80.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.49 (Mar 24) to 0.13, marking an increase of 157.62.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.61 (Mar 24) to 0.13, marking an increase of 157.74.
• For PBDIT Margin (%), as of Mar 25, the value is 16.71. This value is within the healthy range. It has increased from -6.96 (Mar 24) to 16.71, marking an increase of 23.67.
• For PBIT Margin (%), as of Mar 25, the value is 8.98. This value is below the healthy minimum of 10. It has increased from -14.98 (Mar 24) to 8.98, marking an increase of 23.96.
• For PBT Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 10. It has increased from -37.89 (Mar 24) to 0.04, marking an increase of 37.93.
• For Net Profit Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from -43.98 (Mar 24) to 0.04, marking an increase of 44.02.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 8. It has increased from -44.02 (Mar 24) to 0.04, marking an increase of 44.06.
• For Return on Networth / Equity (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 15. It has increased from -60.75 (Mar 24) to 0.04, marking an increase of 60.79.
• For Return on Capital Employeed (%), as of Mar 25, the value is 8.95. This value is below the healthy minimum of 10. It has increased from -17.42 (Mar 24) to 8.95, marking an increase of 26.37.
• For Return On Assets (%), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -24.13 (Mar 24) to 0.02, marking an increase of 24.15.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.70. This value is within the healthy range. It has decreased from 1.07 (Mar 24) to 0.70, marking a decrease of 0.37.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has increased from 0.49 (Mar 24) to 0.56, marking an increase of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 24) to 0.77, marking an increase of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.35 (Mar 24) to 0.43, marking an increase of 0.08.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 4. It has increased from 1.66 (Mar 24) to 1.72, marking an increase of 0.06.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.87. This value is below the healthy minimum of 3. It has increased from -0.85 (Mar 24) to 1.87, marking an increase of 2.72.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.00. This value is below the healthy minimum of 3. It has increased from -2.58 (Mar 24) to 1.00, marking an increase of 3.58.
• For Enterprise Value (Cr.), as of Mar 25, the value is 3,238.30. It has increased from 2,334.27 (Mar 24) to 3,238.30, marking an increase of 904.03.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.81 (Mar 24) to 2.21, marking an increase of 0.40.
• For EV / EBITDA (X), as of Mar 25, the value is 13.23. This value is within the healthy range. It has increased from -25.99 (Mar 24) to 13.23, marking an increase of 39.22.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 1.89, marking an increase of 0.45.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.42 (Mar 24) to 0.00, marking an increase of 0.42.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness